269 related articles for article (PubMed ID: 16861242)
1. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
[TBL] [Abstract][Full Text] [Related]
2. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis.
Shimizu A; Masuda Y; Mori T; Kitamura H; Ishizaki M; Sugisaki Y; Fukuda Y
J Am Soc Nephrol; 2004 Oct; 15(10):2655-65. PubMed ID: 15466270
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis.
Masuda Y; Shimizu A; Mori T; Ishiwata T; Kitamura H; Ohashi R; Ishizaki M; Asano G; Sugisaki Y; Yamanaka N
Am J Pathol; 2001 Aug; 159(2):599-608. PubMed ID: 11485918
[TBL] [Abstract][Full Text] [Related]
5. A murine model of site-specific renal microvascular endothelial injury and thrombotic microangiopathy.
Hohenstein B; Braun A; Amann KU; Johnson RJ; Hugo CP
Nephrol Dial Transplant; 2008 Apr; 23(4):1144-56. PubMed ID: 18045820
[TBL] [Abstract][Full Text] [Related]
6. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
8. Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis.
Uchimura H; Marumo T; Takase O; Kawachi H; Shimizu F; Hayashi M; Saruta T; Hishikawa K; Fujita T
J Am Soc Nephrol; 2005 Apr; 16(4):997-1004. PubMed ID: 15744001
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
Daniel C; Renders L; Amann K; Schulze-Lohoff E; Hauser IA; Hugo C
Am J Transplant; 2005 Dec; 5(12):2849-61. PubMed ID: 16302997
[TBL] [Abstract][Full Text] [Related]
10. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
Zatelli MC; Minoia M; Martini C; Tagliati F; Ambrosio MR; Schiavon M; Buratto M; Calabrese F; Gentilin E; Cavallesco G; Berdondini L; Rea F; degli Uberti EC
Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
[TBL] [Abstract][Full Text] [Related]
11. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis.
Kunter U; Rong S; Djuric Z; Boor P; Müller-Newen G; Yu D; Floege J
J Am Soc Nephrol; 2006 Aug; 17(8):2202-12. PubMed ID: 16790513
[TBL] [Abstract][Full Text] [Related]
12. The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat.
Wittmann S; Daniel C; Braun A; Vogelbacher R; Shimizu F; Kawachi H; Hugo C
Nephron Exp Nephrol; 2008; 108(2):e45-56. PubMed ID: 18270495
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM
J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
[TBL] [Abstract][Full Text] [Related]
15. Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis.
Rookmaaker MB; Smits AM; Tolboom H; Van 't Wout K; Martens AC; Goldschmeding R; Joles JA; Van Zonneveld AJ; Gröne HJ; Rabelink TJ; Verhaar MC
Am J Pathol; 2003 Aug; 163(2):553-62. PubMed ID: 12875975
[TBL] [Abstract][Full Text] [Related]
16. VEGF(165) mediates glomerular endothelial repair.
Ostendorf T; Kunter U; Eitner F; Loos A; Regele H; Kerjaschki D; Henninger DD; Janjic N; Floege J
J Clin Invest; 1999 Oct; 104(7):913-23. PubMed ID: 10510332
[TBL] [Abstract][Full Text] [Related]
17. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy.
Kim YG; Suga SI; Kang DH; Jefferson JA; Mazzali M; Gordon KL; Matsui K; Breiteneder-Geleff S; Shankland SJ; Hughes J; Kerjaschki D; Schreiner GF; Johnson RJ
Kidney Int; 2000 Dec; 58(6):2390-9. PubMed ID: 11115072
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.
Eremina V; Cui S; Gerber H; Ferrara N; Haigh J; Nagy A; Ema M; Rossant J; Jothy S; Miner JH; Quaggin SE
J Am Soc Nephrol; 2006 Mar; 17(3):724-35. PubMed ID: 16436493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
